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The roles of miRNAs in lung cancer have not yet been explored systemati-
cally at the genome scale despite their important regulatory functions. Here,
we report an integrative analysis of miRNA and mRNA sequencing data
for matched tumor–normal samples from 109 Korean female patients with
non-small-cell lung adenocarcinoma (LUAD). We produced miRNA
sequencing (miRNA-Seq) and RNA-Seq data for 48 patients and RNA-Seq
data for 61 additional patients. Subsequent differential expression analysis
with stringent criteria yielded 44 miRNAs and 2322 genes. Integrative gene
set analysis of the differentially expressed miRNAs and genes using
miRNA–target information revealed several regulatory processes related to
the cell cycle that were targeted by tumor suppressor miRNAs (TSmiR).
We performed colony formation assays in A549 and NCI-H460 cell lines to
test the tumor-suppressive activity of downregulated miRNAs in cancer and
identified 7 novel TSmiRs (miR-144-5p, miR-218-1-3p, miR-223-3p, miR-
27a-5p, miR-30a-3p, miR-30c-2-3p, miR-338-5p). Two miRNAs, miR-30a-
3p and miR-30c-2-3p, showed differential survival characteristics in the
Tumor Cancer Genome Atlas (TCGA) LUAD patient cohort indicating
their prognostic value. Finally, we identified a network cluster of miRNAs
and target genes that could be responsible for cell cycle regulation. Our
study not only provides a dataset of miRNA as well as mRNA sequencing
from the matched tumor–normal samples, but also reports several novel
TSmiRs that could potentially be developed into prognostic biomarkers or
therapeutic RNA drugs.
Abbreviations
DEG, differentially expressed gene; DEmiR, differentially expressed miRNA; LUAD, lung adenocarcinoma; qRT-PCR, quantitative real-time
PCR; TCGA, Tumor Cancer Genome Atlas; TSmiR, tumor suppressor miRNA.
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1. Introduction
miRNAs are an important class of regulators deter-
mining cellular fates in almost all biological processes.
A typical miRNA negatively regulates expression of
multiple target genes by binding to mRNAs and
inhibiting translation or inducing mRNA degradation.
A number of miRNAs have been reported to con-
tribute to tumor development, disease progression, and
treatment response in nearly all human cancers and
have emerged as promising and biologically relevant
biomarkers (Kasinski and Slack, 2011).
Most previous studies are based on investigating
miRNAs that are predicted to target known cancer-
related pathways, oncogenes, and tumor suppressor
genes. For example, the let-7 miRNA plays a tumor-
suppressive role in lung cancer by targeting RAS and
cMYC genes, which are critical regulators of the
prominent oncogenic pathway of RAS-RAF-MEK-
ERK signaling (He et al., 2010; Johnson et al., 2005;
Kumar et al., 2008). On the other hand, the tumor
suppressor TP53 gene often described as ‘the guardian
of the genome’ is regulated directly and indirectly by
multiple miRNAs constituting an intricate regulatory
network to mediate the tumor-suppressive role of p53
(Hermeking, 2012; Liu et al., 2017).
Gene expression profiling is a powerful yet unbiased
method to identify miRNAs of functional significance.
miRNA microarrays, although frequently utilized
owing to their cost-effectiveness, usually suffer from
uneven hybridization. This is in large part due to the
extremely limited probe design based on the short
length of 22 nucleotides in mature miRNAs (Yanai-
hara et al., 2006). Deep sequencing is a potentially
ideal method, but the isolation of mature miRNAs
and sequencing much shorter reads than in mRNA
sequencing are challenging (Ma et al., 2014).
A number of miRNAs were implicated in lung ade-
nocarcinoma (LUAD). Analysis of miRNA-Seq data
from the Tumor Cancer Genome Atlas (TCGA)
LUAD cohort yielded many differentially expressed
miRNAs (DEmiR) with prognostic value including
miR-31, miR-196b, miR-101-1, miR-187, miR-331,
miR-375, miR-519a-1, miR-551b, miR-766, and miR-
3653 (Li et al., 2014; Lin et al., 2016). However, most
of these miRNAs were not validated from independent
data sets to be established as reliable prognostic mark-
ers. Several miRNAs were additionally implicated to
have roles in tumorigenesis of LUAD by targeting
known cancer-related pathways. Examples include
miR-195 targeting CCND3 and BIRC5 (Yu et al.,
2018), miR-378 targeting RBX1 and miR-1827
targeting CRKL (Ho et al., 2018), miR-383-5p target-
ing PPP2CA (Zhao et al., 2017), miR-23b and
miR125a-5p targeting KRAS and NF-kB pathways
(Naidu et al., 2017). Many of these studies, however,
were based on functional assays using cell lines, thus
having limited applicability to patients.
Simultaneous profiling of miRNAs and mRNAs
provides an opportunity to compare the gene expres-
sion of miRNAs and their target mRNAs without
extra efforts in filtering out false positives from
miRNA–target prediction. Cancer genome projects of
the TCGA consortium are good examples, but the
portion of patients with both miRNA and mRNA
sequenced is limited. Furthermore, sequencing matched
tumor–normal samples is important to avoid any indi-
vidual-specific biases, but the number of patients with
matched sequencing is again rather small especially in
the case of miRNA-Seq. Taking the TCGA LUAD
cohort as an example, mRNA sequencing (RNA-Seq)
data are available for 515 tumor and 59 normal sam-
ples, including 58 matched pairs. For miRNA-Seq
data, it includes 450 tumor and 46 normal samples,
including 39 matched pairs (Cancer Genome Atlas
Research, 2014). Only 12 patients have both mRNA-
Seq and miRNA-Seq data for matched tumor–normal
samples. This highlights the difficulties in sample
acquisition and sequencing suitable for study designs
involving simultaneous profiling of miRNAs and
mRNAs.
Here, we performed an integrative analysis on
miRNA and mRNA sequencing data for matched
tumor–normal samples from 109 LUAD patients
and report several tumor suppressor miRNAs (TSmiR)
validated from functional experiments. We further
identify candidate miRNAs that could be developed
into prognostic biomarkers for patient stratification
or therapeutic RNA drugs for repressing target
oncogenes.
2. Materials and methods
2.1. miRNA-Seq and mRNA-Seq data production
Patient samples were obtained from LUAD patients
who had undergone curative surgery in Samsung Med-
ical Center (Seoul, Korea). All samples were collected
with the written informed consent from patient and
the prior approval of the institutional review board
(Samsung Medical Center Institutional Review Board)
in accordance with the Declaration of Helsinki.
RNA purity was determined by assaying 1 lL of
the total RNA extract on a NanoDrop ND-1000 spec-
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trophotometer (ThermoFisher, Waltham, MA, USA).
Total RNA integrity was checked using a Bioanalyzer
2100 with an RNA Integrity Number value greater
than 8 (Agilent, Santa Clara, CA, USA). Then,
mRNA sequencing libraries were prepared according
to the manufacturer’s instructions using the Illumina
Truseq RNA Prep kit v2. The quality of the amplified
libraries was verified again with an Agilent Bioanalyzer
2100. Sequencing of pooled libraries was performed on
the HiSeq 2000 sequencing system with paired-end
reads of 100 bp length (Illumina, San Diego, CA,
USA).
Small RNA sequencing libraries were prepared
according to the manufacturer’s instructions using the
Illumina Small RNA Prep kit. cDNA size selection
was carried out with the Sage Science’s Pippin prep
electrophoresis platform. Sequencing of pooled
libraries was performed on the HiSeq 2000 sequencing
system (Illumina) with single-end reads of 50 bp
length. Deep sequencing data were deposited at the
Gene Expression Omnibus (GSE110907).
2.2. Transcriptome data processing
The in-house workflows for analyzing miRNA-Seq
and RNA-Seq data are illustrated in Fig. S1. For
miRNA-Seq data, sequencing reads had adapter
sequences removed and been mapped to the miRBase
release 19 (Kozomara and Griffiths-Jones, 2011) using
BOWTIE V.0.12.9 (Langmead et al., 2009) with the per-
fect match option. The mapping rates ranged from
63% to 70%. miRNA abundance was quantified using
the quantile normalization method in R. mRNA-Seq
data were mapped to the NCBI GRCh 37 genome
using MAPSPLICE version v2.1.6 and the gene model in
Ensembl GRCh 37.72. Transcript abundance was esti-
mated at the gene level by RSEM version 1.2.5 (Li and
Dewey, 2011). Statistics of mapped reads and mapping
rates are summarized in Table S1.
2.3. Identification of differentially expressed
miRNAs and genes
We developed a stringent pipeline to identify DEmiRs
and genes (DEGs), taking advantage of the matched
nature of tumor and normal samples (Fig. S2). Three
different programs, EDGER (Version 3.16.5) (Ritchie
et al., 2015), VOOM (limma 3.30.13) (Ritchie et al.,
2015), and DESEQ2 (Version 1.14.1) (Anders and
Huber, 2010), were used to select DEmiRs with false
discovery rate (FDR) ≤105 after initial filtering of
lowly expressed miRNAs. Taking common miRNAs
from the three program outputs yielded 142 DEmiRs.
We further filtered out lowly expressed DEmiRs by
requiring an overall average expression level of
logCPM (counts per million) ≥3. Then, we further
applied two consistency criteria—(a) the direction of
up/down regulation between tumor and normal tissues
consistent in over 80% of the total patients and (b)
the number of patients with over twofold change
equaling over 70% of the total patients. As illustrated
in Fig. S2, the rigorous filtering procedure predomi-
nantly kept commonly predicted miRNAs from the
three algorithms.
For mRNA sequencing data, we applied a slightly
modified pipeline. Instead of looking at the overall
average expression level, we required the overall aver-
age fold change to be |logFC| > 0.5. The consistency
criteria were each relaxed by 10% to allow for more
DEGs. The pipeline and number of DEGs at each step
are illustrated in Fig. S2.
2.4. Compiling and predicting miRNA–target
genes
Two main sources of miRNA–target information
were miRGator 3.0 (Cho et al., 2013) and the latest
TargetScan 7.0 (Garcia et al., 2011). miRGator 3.0 is
a composite database of miRNA targets encompassing
three literature-based knowledgebases (Tarbase, miRe-
cords, and miRTarBase) and six prediction programs
(TargetScan 6.2, PITA, PicTar, miRNA.org, miRDB,
and Microcosm Targets). miRNA targets commonly
predicted by three or more programs are regarded as
reliable and merged into miRNA targets in the knowl-
edgebases. In order to make up for not being up-to-
date in the miRGator 3.0 content, we further imported
the prediction results from the latest TargetScan 7.0
(cumulative weighted context score >0.2 as suggested
by the developers). Our final compilation included
248 543 miRNA–target relations covering 687 miR-
NAs and 16 563 target genes.
For selecting target genes of tumor-suppressive
DEmiRs for validation experiments, we used a new
conservative prediction program based on a recent
study that explored miRNA–target space extensively
(Kim et al., 2016). In essence, it calculates the multiple
linear regression (MLR) score for a target mRNA by
considering four biological contexts (local AU content
of the flanking region of the miRNA–target site,
30UTR length, target-site abundance, and thermody-
namic pairing stability between the miRNA and the
target mRNA). Only the 8mer, 7mer-m8, and 7mer-A1
site types were considered in regression because the
6mer site type was known to exert relatively weak
repression on their target mRNAs and thus can act as
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noise in target prediction (Bartel, 2009). We selected
mRNAs with MLR score <0.3 as putative targets of
DEmiRs for further validation experiments.
2.5. Cell culture, transfection, and colony
formation assay
Human lung cancer cell lines A549 and NCI-H460
were obtained from the American Type Culture Col-
lection (Manassas, VA, USA). Cells were maintained
at 37 °C and 5% CO2 in RPMI 1640 supplemented
with 10% fetal bovine serum (Hyclone, Logan, UT,
USA) and 1% penicillin/streptomycin (Gibco, Invitro-
gen Corporation, Grand Island, NY, USA).
miRNA mimics were transfected into 1 9 105 cells
in a 35-mm dish using Lipofectamine RNAiMAX
(Invitrogen, Carlsbad, CA, USA) at the concentration
of 40 nM for 48 h according to the manufacturer’s
instructions. Candidate TSmiR mimics and the nega-
tive control (NC) mimics were purchased from
Ambion (Austin, TX, USA).
Two days after transfection with miRNA or NC
mimics, 500 cells were replated in a 35-mm dish in
duplicate and incubated at 37 °C and 5% CO2 for 6–
8 days. Colonies were stained with 0.1% Coomassie
Blue in a 45% methanol and 10% acetic acid solution,
and colony numbers were determined using the Gel
Doc XR system (Bio-Rad, Hercules, CA, USA) with
the Quantity One 1-D analysis software (Bio-Rad).
Each experiment was performed in triplicates.
2.6. RNA extraction and quantitative reverse
transcriptase–PCR (qRT-PCR)
Total RNA was extracted from the miRNA mimic-
transfected cells using the miRNeasy Mini kit (Qiagen,
Valencia, CA, USA) according to the manufacturer’s
instructions. Single-stranded cDNAs were synthesized
from 1 lg of the total RNA using the ImProm-IITM
reverse transcriptase (Promega, Madison, WI, USA).
For quantitative analysis of miRNA–target mRNA
levels, cDNAs generated from 10 ng of the total RNA
were subjected to PCR amplification using the CFX96
Real-time PCR detection system (Bio-Rad) with the
SYBR Select Master Mix (Applied Biosystems by Life
Technologies, Austin, TX, USA; Table S2). ACTB
and HPRT1, two housekeeping genes, were used as
dual reference genes. Cycling conditions were as fol-
lows: pre-denaturation for 2 min at 95 °C, a 2-step
reaction (40 cycles) for 10 s at 95 °C and 40 s at
60 °C, and a dissociation peak analysis. mRNA
expression values of target genes were calculated with
the Bio-Rad CFX Manager Software.
3. Results
3.1. Patient cohort and transcriptome sequencing
Matched tumor–normal samples were obtained from
109 LUAD patients who had undergone curative
surgery. All samples were collected with written
informed consent from the patients and prior approval
of the institutional review board (Samsung Medical
Center). All cases were first-time lung cancer patients
and were females. Most patients were never-smokers
except eight smoker cases. Clinicopathological charac-
teristics of what we call ‘ES_Korea’ samples are
summarized in Table 1 (with further details provided
in Table S3).
We performed both miRNA-Seq and mRNA-Seq
for the matched tumor–normal samples from 48 indi-
viduals. For the remaining 61 individuals, we produced
only mRNA-Seq data for the matched tumor–normal
samples. We also downloaded the miRNA-Seq data
from the TCGA LUAD consortium (version
2016_01_28 from the Broad GDAC Firehose), which
included 39 cases with sequencing data from both
matched tumor–normal samples. Both ES_Korea and
the TCGA miRNA-Seq data sets were processed using
our own computational pipeline as described in the
Materials and methods section.
Table 1. Patient characteristics of the Korean and Tumor Cancer
Genome Atlas cohorts.
Characteristic
ES_Korea
TCGA_LUAD
miRNA
(n = 48)
mRNA
(n = 109)
miRNA
(n = 39)
Sex
Female 48 (100%) 109 (100%) 20 (51%)
Male – – 19 (49%)
Age at diagnosis
Median 59 61.5 66
Range 37–78 29–83 47–85
Stage
I 30 (63%) 72 (66%) 24 (62%)
II 6 (12%) 15 (14%) 10 (25.5%)
III 12 (25%) 22 (20%) 5 (12.5%)
Ethnicity
Black or African
American
– – 6 (15%)
White – – 33 (85%)
Asian 48 (100%) 109 (100%) –
Smoking status
Never-smoker 41 (85%) 102 (94%) 2 (5%)
Smoker 7 (15%) 7 (6%) 34 (87%)
Unknown – – 3 (8%)
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3.2. Identification of differentially expressed
miRNAs and genes
The matched tumor–normal samples enabled us to
obtain a robust list of DEmiRs and mRNAs (DEGs).
We devised a stringent computational pipeline to pre-
dict DEmiRs and DEGs, combining three different
programs and rigorous filtering steps such as a consis-
tency criterion that required consistent direction of
expression change in more than 80% of the total
patients (Fig. S1). Analyzing miRNA-Seq data from
the ES_Korea cases with our pipeline, we obtained 44
highly reliable DEmiRs including 18 up- and 26 down-
regulated miRNAs in tumor (Table S4). The MA plot
shows the average fold change vs. the average
expression level of these DEmiRs (Fig. 1A). The heat-
map and multidimensional scaling views indicate that
tumor and normal samples were perfectly classified
into two groups according to the expression of these
44 DEmiRs (Fig. 1B,C).
Identical analysis of miRNA-Seq data from 39
patients of the TCGA LUAD yielded 47 DEmiRs (19
up- and 28 downregulated ones), 25 of which over-
lapped with the ES_Korea DEmiRs. Expression of
DEmiRs in tumor and normal tissues is depicted in
the box plot (Figs 2 and S3), and we observed that
most miRNAs are consistently differentially regulated
between ES_Korea and TCGA LUAD data sets except
a few cases (miR-450b-5p, miR-486-3p, and miR-
511-5p).
Fig 1. miRNA expression in 48 Korean patients of LUAD. (A) The MA plot where the log fold change (log2 exp_tumor/exp_normal) and the
average expression (½log2 exp_tumor9exp_normal) are shown in the y-axis and x-axis, respectively. Average miRNA expression values over
48 individuals were used in the plot. DEmiRs were indicated in red (upregulated in tumor) and blue (downregulated in tumor) colors.
(B) Representation of tumor and normal samples in two-dimensional space obtained by a multidimensional scaling method. (C) Hierarchical
clustering of samples using 44 DEmiRs.
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Paired RNA-Seq data were subjected to the computa-
tional pipeline for DEGs, where the filtering criteria were
alleviated a little bit to prevent missing genuine miRNA
targets (Fig. S2). We obtained 2322 DEGs as the final
result (935 upregulated and 1387 downregulated genes).
Next, we characterized biological processes repre-
sented by the 2322 DEGs. Functional enrichment analy-
sis for 935 up- and 1387 downregulated DEGs using 50
hallmarks gene sets of MSigDB revealed 24 hallmark
signatures (Fig. 3). Representative activated processes
included cell cycle regulators such as the G2M_check-
point, E2F_targets, and the mitotic spindle. Most pro-
cesses related to inflammation and immune signaling
were downregulated. Epithelial–mesenchymal transi-
tion, estrogen responses, KRAS signaling, and hypoxia
signaling showed mixed enrichments, suggesting their
important but complicated regulatory roles.
3.3. Integrative analysis of miRNA and mRNA
expression using miRNA–target information
Molecular and cellular functions of miRNAs are typi-
cally inferred through functions of their target
mRNAs. However, accurate prediction of miRNA tar-
gets is challenging because miRNA targeting is medi-
ated in a complicated manner by many functional site
types and there are still unknown biological features
that affect the efficacy of miRNA targeting (Kim
et al., 2016). Having both miRNA–Seq and mRNA-
Seq data from matched tumor–normal samples is a
big advantage because it provides an opportunity to
explore the negative correlation of miRNA and
mRNA expressions, a condition that meaningful
miRNA–mRNA target pairs must satisfy.
We sought miRNA and target gene pairs (a) where
both the miRNA and the target gene were differen-
tially regulated, (b) whose directions of differential
expression were opposite to each other, and (c) that
were associated by miRNA targeting as compiled by
merging contents in miRGator 3.0 and the latest Tar-
getScan 7.0 predictions (Materials and methods sec-
tion). We identified 1948 DEmiR-DEG paired
relations, covering 44 DEmiRs (22 and 22 up- and
downregulated in tumor, respectively) and 1014 DEGs
(452 and 562 up- and downregulated in tumor,
respectively). Such DEmiR-DEG pairs have a good
Fig 2. Expression box plots for 26 miRNAs downregulated in tumor samples of the ES_Korea cohort. Tumor and normal samples are
indicated in red and blue colors, respectively. miRNA expression in the TCGA cohort (39 patients with the matched tumor–normal samples)
is shown on the right for comparison. The heatmap in the middle shows the q-value of the FDR test for differential expression in log10(q-
value). Note that box plots for miRNAs upregulated in tumor samples are provided in Fig. S3.
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chance to be functional in the pathophysiology of
LUAD.
We performed gene set analysis for the 1014 target
DEGs regulated by DEmiRs using the MSigDB hall-
mark gene sets (Fig. 3). Enriched biological processes
for miRNA–target DEGs included the G2M_
checkpoint and E2F_targets for activated pathways
and TNFa_signaling_via_NFjB and Inflammatory_re-
sponse for suppressed processes. DEmiRs that target
genes in each enriched process were investigated using
our compilation of miRNA–target information and
the recently updated miRTarBase 7.0 knowledgebase
(Fig. 3 and Table S5) (Chou et al., 2018). To identify
biological processes under miRNA regulation, we
looked for biological processes enriched by both
DEGs and DEmiR targets. We identified several
miRNAs known to target specific processes from lit-
erature survey (marked as an asterisk in Fig. 3). For
example, miR-138-5p and miR-144-3p are known to
target the EZH2 gene (Guo et al., 2013; Liang et al.,
2013) and miR-30a-5p targets the MYBL gene to reg-
ulate the G2M_checkpoint and E2F_target processes
(Martinez et al., 2011). However, many processes did
not have literature basis to identify regulatory
miRNAs and their targets, including the p53_path-
way, glycolysis, estrogen_responses, KRAS_signaling,
TNFa_signaling, inflammatory_response, and IL2_
STAT5_signaling (Table S5). Thus, our analysis pro-
vides an ample opportunity for further functional
studies.
3.4. Colony formation assay for DEmiRs
identified 8 tumor suppressor miRNAs
Tumor suppressor miRNAs are of particular interest
because they could potentially be developed into prog-
nostic biomarkers or therapeutic RNA drugs since
miRNA mimics can be used as anticancer agents
(Adams et al., 2017). Colony formation assay was per-
formed to screen for miRNAs with growth suppression
ability. We subjectively selected 14 candidate miRNAs
from the 26 downregulated DEmiRs from the
ES_Korea data set based on the fold change ratio
(logFC < 2), average expression level (logCPM > 10),
Fig 3. Functional enriched terms of hallmark signatures from MSigDB and relevant miRNAs. The heatmap on the left indicates the q-value
of enrichment in log10(q-value) for DEGs where up- and downregulations in tumor samples are shown in red and blue colors, respectively.
The first and third columns were calculated using all DEGs (935 up- and 1387 downregulated DEGs), and the second and fourth columns
were obtained by using subset of DEGs that were targets of DEmiRs (452 up- and 562 downregulated DEGs). The black and white
heatmap on the right indicates presence or absence of miRNAs targeting DEGs involved for each process where validated and predicted
targets are indicated in black and gray colors, respectively. Target genes with literature evidence are marked with an asterisk where further
details were provided in Table S5.
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and literature evidence (Table S6). Known TSmiRs were
excluded from the candidates except miR-486-5p, which
was used as a positive control.
Colony formation assays using A549 and NCI-H460
human lung cancer cell lines revealed seven novel
TSmiRs (miR-338-5p, miR-30a-5p, miR-30c-2-3p,
miR-144-5p, miR-27a-5p, miR-223-3p, miR-218-1-3p),
in addition to miR-486-5p used as the positive control,
with tumor suppressor activity in both cell lines
(Fig. 4A). High success rate, 8 out of 14 candidates,
likely stemmed from the stringency in selecting
DEmiRs from our data set.
Next, we investigated whether the expression level of
the eight TSmiRs could serve as a prognostic marker
for predicting patient survival. Using OncoLnc (http://
www.oncolnc.org/) that provided online survival anal-
ysis for the TCGA patients (490 LUAD cases
analyzed), we found that survival curves of two miR-
NAs, miR-30a-3p and miR-30c-2-3p, showed meaning-
ful separation between patient groups of top and
bottom 10 percentiles in miRNA expression (Fig. 4B,
C). Furthermore, SERPINH1, one of the predicted
target genes of miR-30c-2-3p, showed a clear separa-
tion between patient groups of top and bottom 20 per-
centiles (Fig. 4D). These data strongly suggest that
miR-30c-2-3p could be a TSmiR with prognostic value
in LUAD.
3.5. Validation of candidate target genes for
miRNAs with tumor suppressor activity
In an effort to identify target genes for TSmiRs
whose activity was validated from the colony forma-
tion assay, we performed quantitative RT-PCR to
Fig 4. Functional and survival characteristics of TSmiR candidates. (A) Colony number relative to negative controls in the colony formation
assay for A549 (top) and NCI-H460 (bottom) cell lines. Error bars indicate the standard error of the mean. Each measurement was done in
triplicate, and the P-value was calculated with two-tailed t-test. (B-D) Kaplan–Meier survival plots using the TCGA LUAD patients by
expression value of miR-30a-3p (B), miR-30c-2-3p (C), SERPINH1 (D), and the target gene of miR-30c-2-3p.
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quantify mRNA expression changes resulting from
transfection of a miRNA mimic of interest. For five
miRNAs (miR-30c-2-3p, miR-144-5p, miR-486-5p,
miR-27a-5p, miR-218-1-3p) that significantly reduced
colony-forming ability in two lung cancer cell lines,
we selected 42 candidate target genes using a state-of-
the-art algorithm to predict miRNA–target genes
(Materials and methods section) (Kim et al., 2016).
We identified 17 target genes that showed reduced
mRNA expression upon transfection with a miRNA
mimic by more than 30% compared to the control
sample in both cell lines (Fig. 5). Notably, SER-
PINH1 gene was one of the validated targets of
miR-30c-2-3p, again indicating its oncogenic function
in agreement with the tumor-suppressive role of
miR-30c-2-3p.
Several target genes (E2F8, MYBL2, HMGB3, and
TOP2A) belonged to the gene sets of E2F_Targets and
the G2M_Checkpoint, which were inferred from the
MSigDB enrichment analysis. We constructed a net-
work model for regulating the cell cycle by collecting
miRNAs and their target genes, which were validated
experimentally (Fig. 6). This network module is highly
likely to be functional in tumorigenesis of lung cancer
since all miRNA and genes were differentially regu-
lated between tumor and normal tissues (see the Dis-
cussion section below).
4. Discussion
Studies that have sequenced mRNAs and miRNAs
simultaneously are uncommon even though its benefit
is well acknowledged. This is most likely due to the
difficulties in generating miRNA–Seq data. Experimen-
tal design of matched tumor–normal samples requires
additional efforts in the sample acquisition process.
Thus, our data set, providing both miRNA–Seq and
mRNA-Seq data for matched tumor–normal samples
from 48 Korean patients with LUAD, is a unique
resource that includes ideal control data to avoid per-
son-to-person variations when comparing tumor vs.
normal or mRNA vs. miRNA expressions. This may
serve as an optimal data set to test and evaluate
advanced algorithms for identifying miRNA targets,
discovering cancer biomarkers, or deciphering molecu-
lar mechanisms in tumorigenesis.
Fig 5. Relative change of target gene expression in qRT-PCR experiment when cells were transfected with miRNA mimic in A549 (top) and
NCI-H460 (bottom) cell lines. Each measurement was done in triplicate and the P-value was calculated with two-tailed t-test.
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Our efforts were focused on identifying TSmiRs and
target oncogenes that could be developed into prog-
nostic biomarkers or therapeutic targets of cancer
drugs. We identified seven novel TSmiRs with demon-
strated tumor-suppressive activity and 17 target genes
whose expression was dependent on miRNA transfec-
tion in two lung cancer cell lines. Many of those
TSmiRs and target genes were reported as prognostic
markers in diverse types of tumor. Examples include
miR-30c-2-3p in breast cancer (Shukla et al., 2015),
miR-218 in hepatocellular carcinoma (Yang et al.,
2016), CXCL14 in colorectal carcinoma (Zeng et al.,
2013), and SERPINH1 in clear cell renal cell carci-
noma (Qi et al., 2018).
Biological regulation is an elaborate process typi-
cally involving a complex network of regulatory loops.
TP53 is a good example where more than 20 miRNAs
are known to regulate TP53 by binding directly or tar-
geting indirectly regulators of the p53 gene (Hermek-
ing, 2012; Liu et al., 2017). On the other hand, TP53
itself regulates the transcriptional expression of a
group of miRNAs, thus creating feedback loops.
We have discovered several DEmiRs and their target
genes that are involved in cell cycle regulation (Fig. 6).
E2F8 is a transcription factor for the HMGB3 gene
whose overexpression is associated with poor progno-
sis in diverse types of cancer including non-small cell
lung cancer (Song et al., 2013). Notably, HMGB3 is
the target of miR-338-5p that was consistently down-
regulated in LUAD (46 out of 48 patients). This
miRNA is an intronic miRNA within the AATK gene
that is also downregulated in tumor. Tumor-suppres-
sive roles of the hosting AATK gene are well estab-
lished in melanoma and lung cancer cells (Haag et al.,
2014; Ma and Rubin, 2014). We also observed that the
AATK gene is the target of miR-182-5p that is upreg-
ulated in cancer. Thus, a regulatory cascade of miR-
182-5p, the AATK gene, miR-338-5p and the E2F8
transcription factor possibly leads to overexpression of
HMGB3.
Fig 6. A network model of regulating cell cycles. All miRNAs and their target genes are differentially expressed between tumor and normal
samples in concordant direction with negative regulation of miRNAs.
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Another regulatory network for the cell cycle con-
sists of MYBL2 and TOP2A, which are targets of
miR-30c-2-3p and miR27a-5p, respectively. Both genes
are involved in the G2M_Checkpoint, and all members
were differentially expressed in our data. MYBL2 is
known to promote cell proliferation and EMT in
many tumor types (Jin et al., 2017; Liang et al., 2017;
Tao et al., 2015), and TOP2A is associated with worse
prognosis in non-small-cell lung cancer patients (Hou
et al., 2017).
Altogether, we present two regulatory paths respon-
sible for cell cycle regulation. The detailed interplay of
these regulatory elements remains to be elucidated, but
our network model should enhance current under-
standing of the regulatory roles of miRNAs in LUAD.
5. Conclusions
Our study reports integrative analyses of high-through-
put sequencing data of miRNA and mRNA from 49
tumor–normal paired LUAD samples, which is the lar-
gest patient cohort of this kind for LUAD to date. We
further identified and experimentally validated seven
novel TSmiRs, two of which (miR-30a-3p and miR-
30c-2-3p) showing merits of prognostic molecular
markers as well as potential targets for therapeutic
manipulations. Multilayered deep sequencing with
proper control samples followed by in-depth integra-
tive analysis proves to be a powerful approach to
delineate molecular mechanisms behind cancer etiology
and to identify molecular biomarkers of prognostic
value.
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